Pasithea Therapeutics Announces Opening Of Enrollment In The U.S. For Its Phase 1 Trial Of PAS-004
Pasithea Therapeutics Announces Opening Of Enrollment In The U.S. For Its Phase 1 Trial Of PAS-004
Pasithea Therapeutics 宣布其 PAS-004 一期试验在美国开放注册
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy --
— 激活 PAS-004 1 期临床试验的四个美国站点，以评估安全性、剂量、关键生物标志物数据和初步疗效——
-- Plans to open three additional sites in Eastern Europe in the coming months --
-计划在未来几个月内在东欧再开设三个基地-
-- Preliminary interim data expected in 2H 2024 --
--预计将在2024年下半年发布初步中期数据--
SOUTH SAN FRANCISCO, Calif. and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the activation of four clinical trial sites in the United States. These U.S. clinical trial sites...
加利福尼亚州南旧金山和迈阿密，2024 年 2 月 13 日（GLOBE NEWSWIRE）— Pasithea The...
登录免费看全文
登录/注册